期刊文献+

肾病综合征患者血浆中t-PA/PAI-1的变化及糖皮质激素治疗的影响 被引量:10

The Changes of Plasma t-PA/PAI-1 in Nephrotic Syndrome Patients and the Effects of Glucocorticoid
在线阅读 下载PDF
导出
摘要 目的 :探讨肾病综合征患者糖皮质激素治疗前后不同阶段组织型纤溶酶原激活物 (t -PA)与纤溶酶原激活物抑制物 - 1(PA1- 1)的变化。方法 :分为健康对照组、肾病综合征组 ,采用酶联免疫吸附 (ELISA)方法检测血浆中t -PA和PAI - 1水平的变化。结果 :t-PA的血浆水平在各组之间无统计学差异 (P >0 .0 5 ) ;PAI - 1的水平在肾病综合征组较正常明显升高 (P <0 .0 5 ) ,激素治疗 1周后进一步升高 (P <0 .0 5 ) ,治疗 4周后比 1周组有显著下降(P <0 .0 5 ) ,但较正常仍高 (P <0 .0 5 )。结论 :t-PA/PAI - 1平衡的紊乱 ,可能参与了肾病综合征的损伤机制 ,经糖皮质激素治疗后高凝状态短期内无明显改善。 Objective:To investigate the changes of plasma levels of t-PA and PAI-1 in nephrotic syndrome patients and the effects of glucocorticoid on the balance of t-PA/PA-1.Methods:Patients were divided into groups of normal control, pre-treatment, 1 week post-treatment and 4 weeks post-treatment. ELISA was used to measure concentration of t-PA and PAI-1.Results:There was no significant difference in t-PA levels in different groups(P>0.05). The plasma level of PAI-1 in pre-treatment group was significantly higher than that of normal control(P<0.05).In the group of 1 week post-treatment, PAI-1 significantly increased compared to pre-treatment group(P<0.05).But in the group of 4 weeks post-treatment, the concentration of PAI-1 significantly decreased compared to the group of 1 week post-treatment(P<0.05). However, it was still higher than that of normal control(P<0.05).Conclusion:The disturbance of t-PA/PAI-1 balance may be implicated in renal damage of nephrotic syndrome, which can not be improved by glucocorticoid treatment in short time.
出处 《中国中西医结合肾病杂志》 2004年第8期450-451,共2页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 广东省重大专项及重点项目计划 (No .B3 0 3 0 2 ) 广东省医学科研基金资助项目 (No .A199964 7)
关键词 肾病综合征 血浆 T-PA PAI-1 糖皮质激素 治疗 Nephrotic syndrome Tissue plasminogen activator Plasminogen activator inhibitor-1 Glucocorticoid
  • 相关文献

参考文献6

  • 1陈香美.凝血纤溶系统与细胞外基质调控系统在肾脏疾病中的作用[J].中华肾脏病杂志,2001,17(5):348-349. 被引量:61
  • 2Tsuyoshi O, Michael F, Wilbur L, et al. Modulation od plasmanogen activator inhibitor-1 in vivo:A new mechanism for the anti-fibrotic effect of rennin-agiotensin inhibitor.Kidney Int, 1997,51:164-172.
  • 3Yoshida Y, Shiiki H, Iwano M, et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron,2001,88(1):24-29.
  • 4Hamano K, Iwano M, Akai Y, et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis,2002,39(4):695-705.
  • 5Banach-Wawrzenczyk E, Dziedziczko A, et al.Fibrinolytic system in bronchial asthma after prednisone treatment. Pol Merkuriusz Lek,2000,7(43):9-11.
  • 6张冬梅,顾华,孙广东,苗里宁,刘建东.甲基强的松龙对狼疮性肾炎患者血浆中PAI-1的影响[J].中国免疫学杂志,2003,19(5):355-356. 被引量:1

二级参考文献4

  • 1Wong A P, Cortez S L, Barieos W H. Role of plasmin and delatinase in extracellularmtrix degradation by cultured rat mesangial cells[J].Am J Physiol, 1992 ;263: F1 1112-2118.
  • 2Erckson L A, Fici G J,Lund J E et al. Development of renous in mice transgenic for plasminogen activator inhibitor-1 gene[J]. Nature, 1990;346: 74-76.
  • 3Keton M, Ahn C, Egnchi Y et al. Expression of type glasminogen activator inhibitor in renal tissue in murine lupus nephritis[J]. Kindney Int,1995;47:148.
  • 4陈高翔,屈燧林.纤溶酶原激活物抑制剂-1与肾脏疾病[J].肾脏病与透析肾移植杂志,1999,8(2):155-158. 被引量:11

共引文献60

同被引文献79

引证文献10

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部